Avacopan under MHRA benefit-risk review
- Sponsor
- Vifor Pharma $VIFN
- Drug
- Avacopan · avacopan
- Indication
- granulomatosis with polyangiitis
MHRA reviews avacopan's benefit-risk profile following concerns about pivotal trial data integrity.
What this means
Avacopan is a drug that treats rare autoimmune diseases by blocking a part of the immune system that attacks small blood vessels, used alongside other medications. The UK's MHRA is reviewing whether flaws in the original trial data affect the drug's proven benefits versus its risks. This could lead to updated safety advice or changes in how the drug is prescribed, though patients should keep taking it unless their doctor says otherwise.
From the source
Avacopan is used in the treatment of some rare autoimmune diseases affecting small blood vessels.
From: Medicines and Healthcare products Regulatory Agency
Published 5 June 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing the benefits and risks of avacopan (Avacopan Vifor, previously known as Tavneos), which is used in the treatment of some rare autoimmune diseases affecting small blood vessels. This review has been prompted by information that raises questions about the integrity and reliability of the data from the pivotal clinical study underpinning the licence approval.
The MHRA review is considering at whether this information changes what the study showed about the effectiveness of avacopan, and what this means for the overall benefit-risk consideration of the product.
Avacopan, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are rare autoimmune diseases affecting small blood vessels.
The review is being undertaken under the Human Medicines Regulations 2012 Section 68 which states that the licensing authority, the MHRA, may revoke, vary or suspend a UK marketing authorisation if the licensing authority considers that the application, or the material supplied with it, is incorrect or no longer supports a positive benefit–risk balance for the product.
The existing risk minimisation advice in the product information continues to apply while the review is undertaken. This includes monitoring of liver function and white blood cell count, as well assessing patients for any serious infections.
While the review is ongoing, healthcare professionals are reminded to consider carefully the individual patient benefits and risks regarding the use of avacopan.
Patients are advised to not stop treatment without consulting their healthcare professional.
The outcome of the review, including any new advice to healthcare professionals and patients, will be communicated once the review is complete.
Any suspected adverse reactions should be reported via the MHRA Yellow Card scheme.
Updates to this page
Published 5 June 2026
Reproduced from MHRA News · view original · public domain or open-licensed government work
Drug Watch — recent news on Avacopan
- Liver Injury FDA Warning for Tavneos Patients - Pharmacy Practice News
- KFF Analysis Finds Hundreds of Delayed FDA Postmarket Studies - findarticles.com
- The Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done. - KFF Health News
- 20 deaths: Kissei Pharmaceutical urges doctors to halt Tavneos use - 朝日新聞
- FDA-ordered studies of many drugs, devices on the market are not done - The Washington Post